Teva Economic Impact Report

Jul 28, 2021 | Analysis

Teva Economic Impact Report This report, from Matrix Global Advisors (MGA), highlights Teva’s impact on economies in 15 of the 60 countries in which Teva operates. These 15 countries comprise 60 percent of Teva’s total global workforce and 75 percent of revenues in...

Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually

Sep 22, 2020 | News

Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually Scott Wooldridge | BenefitsPro “The report, from Matrix Global Advisors and the Coalition for Affordable Prescription Drugs (CAPD), looked at five prescription drugs:...

Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says

Sep 15, 2020 | News

Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says Maia Anderson | Becker’s Hospital Review “An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S....

New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year

Sep 14, 2020 | Press Releases

New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year Alex Brill | Washington, DC Today, Matrix Global Advisors (MGA) released a new report, “The Cost of Brand Drug Product Hopping,” commissioned by the Coalition for...

New MGA Paper Investigates the Economic and Budgetary Effects of the BLOCKING Act

Jan 13, 2020 | Analysis

New MGA Paper Investigates the Economic and Budgetary Effects of the BLOCKING Act This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition. The report points out that the bill would reduce the incentive for generic...